Literature DB >> 19142641

Tuberculous myositis in a patient with ankylosing spondylitis treated with adalimumab.

Valdeŕilio Feijó Azevedo1, C Parchen, S A Coelho, D C Lacerda, C G Hirth.   

Abstract

We present a rare case of tuberculous myositis in a 36-year-old man with long-standing ankylosing spondylitis treated with adalimumab. We review the association between antitumor necrosis factor therapy and tuberculous myositis. Our case illustrates that the index of suspicion of tuberculosis in these patients, even with atypical clinical features, must be very high and emphasizes that this rare infection may occur even with negative tuberculosis screening before therapy was started.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19142641     DOI: 10.1007/s00296-008-0837-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  19 in total

1.  [Miliary tuberculosis following treatment with adalimumab].

Authors:  U Lertxundi; J Mayo; M García; B Ruiz; C Aguirre
Journal:  Farm Hosp       Date:  2005 Sep-Oct

2.  Tuberculous pyomyositis: an unusual presentation of disseminated Mycobacterium tuberculosis infection.

Authors:  R A Bonomo; R Graham; J T Makley; C A Petersilge
Journal:  Clin Infect Dis       Date:  1995-06       Impact factor: 9.079

3.  Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Authors:  Désirée van der Heijde; Alan Kivitz; Michael H Schiff; Joachim Sieper; Ben A C Dijkmans; Jürgen Braun; Maxime Dougados; John D Reveille; Robert L Wong; Hartmut Kupper; John C Davis
Journal:  Arthritis Rheum       Date:  2006-07

4.  Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study.

Authors:  Jürgen Braun; Robert Landewé; Kay-Geert A Hermann; John Han; Songkai Yan; Paul Williamson; Désirée van der Heijde
Journal:  Arthritis Rheum       Date:  2006-05

5.  Generalised skeletal muscle tuberculosis.

Authors:  D S Gahlaut; K Nath; K K Sikka; K N Singh; K C Samuel
Journal:  J Indian Med Assoc       Date:  1973-07-16

Review 6.  Soft tissue tuberculosis: a series of 11 cases.

Authors:  M P Puttick; H B Stein; R M Chan; R K Elwood; A R How; G D Reid
Journal:  J Rheumatol       Date:  1995-07       Impact factor: 4.666

7.  Tuberculosis in patients treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile?

Authors:  Adriana Rojas-Villarraga; Carlos Andrés Agudelo; Ricardo Pineda-Tamayo; Alvaro Porras; Gustavo Matute; Juan Manuel Anaya
Journal:  Biomedica       Date:  2007-08-21       Impact factor: 0.935

8.  Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

Authors:  John C Davis; Désirée Van Der Heijde; Jurgen Braun; Maxime Dougados; John Cush; Daniel O Clegg; Alan Kivitz; Roy Fleischmann; Robert Inman; Wayne Tsuji
Journal:  Arthritis Rheum       Date:  2003-11

9.  Adalimumab for the treatment of ankylosing spondylitis.

Authors:  Joachim Sieper; Martin Rudwaleit; Jürgen Braun
Journal:  Expert Opin Pharmacother       Date:  2007-04       Impact factor: 3.889

10.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

Authors:  Juan J Gómez-Reino; Loreto Carmona; Vicente Rodríguez Valverde; Emilio Martín Mola; Maria Dolores Montero
Journal:  Arthritis Rheum       Date:  2003-08
View more
  1 in total

1.  Multiple organ tuberculosis of lung, pleura, and peritoneum in ankylosing spondylitis during adalimumab therapy.

Authors:  Wan-Hee Yoo
Journal:  Rheumatol Int       Date:  2010-01-05       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.